Park J, Han JK, Kang J, et al. - Researchers used the Grand-DES registry to determine the effect of β-blockers in acute coronary syndrome (ACS) following percutaneous coronary intervention. This analysis involved a total of 6,690 ACS patients. Experts investigated prescription records of dose and type of β-blockers trimonthly from discharge. Patients were divided based on the mean value of doses during the follow-up as well as vasodilating property of β-blockers. A lower risk of all-cause and cardiac death was observed in patients taking β-blockers vs those not receiving β-blockers. Overall, findings showed better clinical results in relation to β-blocker therapy in patients with ACS, especially with medium-dose and vasodilating β-blockers.